A phase-IV, single-centre, randomised, open-labelled, parallel-arm study to determine clinical effect of a reduced dose regime (1 + 1) of PCV10 and PCV13 along with 3-dose regimes on pneumococcal vaccine-type (VT) carriage and immunogenicity in the first two years of life in PCV-naive Indian children
Latest Information Update: 21 Apr 2023
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- 21 Apr 2023 New trial record
- 10 Apr 2023 Results published in the Vaccine